Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Brain and Spinal Cord Cancer
  •  Leukemia
  •  Hematology
  •  Immunotherapy
  •  Gynecological Cancers
  •  Central Nervous System Tumors
  •  Radiological Techniques and Scans
  •  Radiation Oncology

Abstract

Citation: Clin Oncol. 2021;6(1):1879.DOI: 10.25107/2474-1663.1879

Abdominal Tuberculosis Masquerading as Progression of Carcinoma Prostate

Ankitkumar Sharma and N Kuppurajan

Kovai Medical Center and Hospital, Coimbatore, India

*Correspondance to: Ankitkumar Sharma 

 PDF  Full Text Case Report | Open Access

Abstract:

The presence of pulmonary tuberculosis in cancer patients is a common entity occurring due to the immunosuppression by the cancer itself or secondary immunosuppression from chemotherapy. While there have been many reported cases of pulmonary tuberculosis, the occurrence of abdominal tuberculosis in urologic cancers has not been documented in literature. Here we present the case of a 64 year old male, a known case of castration resistant carcinoma prostate with skeletal metastasis, 10
weeks post chemotherapy, who presented with complaints of abdominal distension for 3 weeks with loss of weight, pedal edema, reduced appetite and generalized body weakness, which was assumed to be disease progression but later diagnosed as abdominal tuberculosis. We hope to highlight the possibility of abdominal tuberculosis in the scenario of urological cancers.

Keywords:

Cite the Article:

Sharna AK, Kuppurajan N. Abdominal Tuberculosis Masquerading as Progression of Carcinoma Prostate. Clin Oncol. 2021;6:1879..

Search Our Journal

Journal Indexed In

Articles in PubMed

NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Erlotinib Treatment Beyond Progression in EGFR Mutant Patients Who Have Responded to EGFR TKIs in Stage IIIB/IV NSCLC: An Open Label Randomized Trial
 Abstract  PDF  Full Text
PEGylation of AS16 Double-Target Peptide that Blocks the Neuropilin-1 and Tie2 Signaling Pathways Enhances its Antitumor Effect
 Abstract  PDF  Full Text
View More...